机构：[1]Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Med Oncol Dept, Beijing, Peoples R China[2]Beijing Shijitan Hosp, Lymphoma Dept, Beijing, Peoples R China[3]Beijing Shijitan Hosp, Phase Clin Trial Ctr, Beijing, Peoples R China[4]Beijing Hosp, Hematol, Beijing, Peoples R China[5]Hebei Univ,Affiliated Hosp,Oncol Dept,Baoding,Peoples R China医疗肿瘤内科河北大学附属医院重点学科肿瘤内科[6]Bengbu Med Coll, Affiliated Hosp 1, Hematol, Bengbu, Peoples R China[7]Beijing Mabworks Biotech Co Ltd, Med Res, Beijing, Peoples R China[8]Beijing InnoCare Pharma Tech Co Ltd, Med Res, Beijing, Peoples R China
第一作者机构：[1]Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Med Oncol Dept, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Shi Y-K.,Qin Y.,Zhang W.,et al.Preliminary phase I/II study results of orelabrutinib combined with MIL62 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma[J].ANNALS OF ONCOLOGY.2021,32:S778-S778.doi:10.1016/j.annonc.2021.08.133.
APA：
Shi, Y-K.,Qin, Y.,Zhang, W.,Wang, X.,Liu, H....&Zhao, R..(2021).Preliminary phase I/II study results of orelabrutinib combined with MIL62 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.ANNALS OF ONCOLOGY,32,
MLA：
Shi, Y-K.,et al."Preliminary phase I/II study results of orelabrutinib combined with MIL62 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma".ANNALS OF ONCOLOGY 32.(2021):S778-S778
医学